Growing Private Pharmaceutical Organization Awards $1.1 Million Study to eResearchTechnology for Cardiac Safety Monitoring and I
27 April 2004 - 12:05AM
PR Newswire (US)
Growing Private Pharmaceutical Organization Awards $1.1 Million
Study to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Thorough Phase I ECG Study for
Key Compound to Be Performed Over 90-Day Period PHILADELPHIA, April
26 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a
leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received an agreement for more than $1.1 million in cardiac safety
monitoring and services from a growing private pharmaceutical
organization for one of its drug candidates in clinical
development. The agreement covers an extensive Phase I study for
which eRT is providing comprehensive support including the
provision, training and ongoing assistance required for effective
use of digital 12-lead Holter equipment designed to facilitate
24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The study is targeted for
completion over a 90-day period. "We are pleased to have been
selected to provide cardiac safety services for the first Thorough
Phase I ECG Study conducted by this recently established and
fast-growing organization," said Scott Grisanti, senior vice
president of business development and chief marketing officer at
eRT. "The combination of eRT's operational expertise in the
demanding Thorough Phase I ECG Study arena and experience in the
anti-infective therapeutic area targeted by this compound, position
our company to make a valuable contribution to this drug
developer's efforts." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Report on Form 10-K filed with the Securities and
Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT:
Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-858-456-4533, for
eResearchTechnology Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles